Director, Chief Executive Officer
Dr. Bing Li has been a member of our Board since July 25, 2018 and our CEO from August 2018. Dr. Li previously served on the Board of the Company from February 2011 to May 2014. Dr. Li served as a managing director of Fosun Group, a China-based international conglomerate and investment company, from March 2016 to December 2017, and a vice president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a Chinese pharmaceutical company, from May 2014 to February 2016. Prior to that, Dr. Li served as an executive director of Warburg Pincus, an American private equity firm, from June 2010 to May 2014, and as a general manager of the Enterprise Business and Business Development division in China and Hong Kong at GlaxoSmithKline, a global pharmaceutical company, from August 2006 to June 2010. From 1999 to 2006, Dr. Li held multiple roles in Eli Lilly and Company, a global pharmaceutical company. Dr. Li received a B.S. in Biophysics from Fudan University, a Ph.D. in Cell and Molecular Biology from University of Rochester, and a MBA and MEM from Northwestern University.
Chief Financial Officer
Mr. Yang has been our CFO since August 7, 2012. Mr. Yang served as our interim CFO between May 31 and August 6, 2012 and our Vice President-Finance & Compliance and Treasurer between March 30, 2012 and August 6, 2012. Mr. Yang also serves as an independent director for Kunming Jida Pharmaceutical. Mr. Yang has six years of financial management experience in corporations and 11 years of audit experience in accounting firms. Mr. Yang has extensive experience in dealing with the PRC tax regulations, PRC GAAP, IFRS and internal control matters. He was an audit senior manager at KPMG, where he provided audit services for initial public offerings, right issues and merger and acquisition transactions. He also worked on the annual reports of various public companies listed in Hong Kong and mainland China. His audit clients ranged from state-owned enterprises and Chinese listed companies to multinational companies, including Angang Steel, Shenhua Energy, BOE Technology and BHP Billiton. Mr. Yang is a certified public accountant in China.
Chief Business Officer
Dr. Huaming (Homer) He has been our Chief Business Officer since December 3, 2018, in charge of the commercial portion of the growing market in China. Dr. He has more than 30 years’ professional experiences in the healthcare industry, especially in the Greater China area. From 2015 to 2018, he worked as the Vice President & General Manager of Danaher Dental Platform which is one of the US Fortune Top 500 corporations, and took responsibilities on its Ormco/ABT/Nobel Biocare businesses in the Greater China area. Before that, he served on several senior commercial positions in multinational corporations such as MSD, a U.S.-headquartered company ranking among the top 10 in the global pharmaceutical market, and GlaxoSmithKline plc (GSK), a leading British pharmaceutical company. Previously Dr. He also worked in China state-owned enterprises such as Shanghai Jing’An Pharmaceutical Co., Ltd. which is invested by Shanghai Leiyunshang Pharmaceutical West Area Co., Ltd., in the areas of pharmaceuticals, vaccines, and medical device consumables. Dr. He possesses a Bachelor Degree of Clinical Medicine from Tongji University as well as an EMBA certificate from a joint program of Shanghai Jiaotong University and Rotman Business School, University of Toronto. He is a Certificated Clinical Doctor in China, with 4 years’ clinical medical experience as a surgeon in hospitals.
General Manager of Shandong Taibang
Mr. Guangli Pang has been the General Manager of Shandong Taibang since 2012. Mr. Pang joined the Shandong Institute of Biological Products (“Shandong Institute”), Shandong Taibang’s predecessor , in 1985, and then joined Shandong Taibang when it was founded in 2002. Mr. Pang graduated from Shandong Medical University, majoring in pharmacy. He has over 30 years of progressively responsible experience in China plasma industry.
Corporate Vice President, General Manager of Guizhou Taibang
Mr. Gang Yang has served as Corporate Vice President since August 2013 and the General Manager of Guizhou Taibang since 2010. Mr. Yang has over 20 years of experience in China plasma industry and previously held various management positions at Guizhou Taibang, including deputy General Manager.
General Manager of Xi'an Huitian
Since 2009, Mr. Jun Zhao has served as the General Manager of Xi’an Huitian. Prior to this role, Mr. Zhao joined Shandong Taibang since its inception in 1987 and has served as manager of quality management and as quality director. He has over 30 years of management, operational, and technical expertise in China’s plasma-based biopharmaceutical industry.